Eisai plays guinea pig in German resubmission process
This article was originally published in Scrip
Executive Summary
Eisai has taken the plunge becoming the first company to resubmit a drug, Fycompa (perampanel) for epilepsy, to Germany's health technology appraisal body via the "normal" resubmission process. The move could be risky, as the Federal Joint Committee (G-BA) could potentially give the drugs a worse outcome than they received in their first benefit assessment.